INMD250117P37500
- 20.20
- 0.000.00%
InMode Newsroom
InMode (NASDAQ:INMD) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Rallies 5.1% This Past Week
InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier Than Originally Announced
InMode Pressed by Investor Doma Perpetual to Launch Tender Offer, Buy Back Stock
Express News | InMode Shareholder DOMA Perpetual Sends Letter Sends To Board Saying It Believes Board Must Immediately Execute Tender Offer For 30% Of The Company
Express News | Doma Perpetual: Inmode Should Immediately Name New Heads of Sales for All Relevant Regions & Present Them to Market
Express News | Doma Perpetual Sends Letter Urging Board of Directors of Inmode Ltd. to Immediately Execute Tender Offer Followed by Share Buyback
DOMA Perpetual Sends Letter Urging Board Of Directors Of InMode Ltd. To Immediately Execute Tender Offer Followed By Share Buyback >INMD
InMode Faces Macroeconomic Challenges and Manufacturing Disruptions, Leading to Hold Rating
Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $26
Express News | Inmode Ltd : Jefferies Cuts Target Price to $16 From $18
InMode Is Maintained at Overweight by Barclays
InMode Price Target Cut to $26.00/Share From $27.00 by Barclays
InMode Analyst Ratings
Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $26
Needham Maintains InMode(INMD.US) With Hold Rating
Needham Remains a Hold on InMode (INMD)
BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)
InMode Lowers 2024 Revenue Guidance; Sets 2025 Revenue Outlook; Shares Slump Pre-Bell
InMode Sees FY24 Adjusted Gross Margin 80%-81%